|EMBL Ventures||Managing Director||Germany|
AGNOSTIC OR PURE PLAYERS IN THE BIOTECH SECTOR: WHO IS BECOMING PROMINENT IN THE EARLY-STAGE FINANCING ROUNDS?
Dear Mr Adams
Jan is a Managing Director with EMBL Ventures, focusing on opportunities in the drug development sector. He was involved with the formation and investment in a number of early stage companies and has been representing the firm on various portfolio boards, e.g., Lipid Therapeutics, Opsona, Arsanis, ViraTherapeutics, Topas Therapeutics and Endoart.
Prior to joining EMBL Ventures, Jan was a postdoctoral Fellow of the Ernst Schering Research Foundation at the University of Granada, Spain. Before that he was a Fellow of the Boehringer Ingelheim Research Foundation, conducting work on molecular transport mechanisms at the Wellcome CRC in Cambridge, UK. He holds a MSc in Biochemistry from the University of Tübingen, and a PhD from the University of Cambridge, UK.